SUMO1 (Protein | Antibody | cDNA Clone | ELISA Kit)

All SUMO1 reagents are produced in house and quality controlled, including 3 SUMO1 Antibody, 60 SUMO1 Gene, 1 SUMO1 IP Kit, 1 SUMO1 Protein, 2 SUMO1 qPCR. All SUMO1 reagents are ready to use.

More Product Popular With Customers

SUMO1 Background

Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.

SUMO1 References

  • Kim HJ, et al. (2011) SUMO1 attenuates stress-induced ROS generation by inhibiting NADPH oxidase 2. Biochem Biophys Res Commun. 410(3): 555-62.
  • Zuo Y, et al. (2009) Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. Asian J Androl. 11(1): 36-8.
  • Song T, et al. (2008) SUMO1 polymorphisms are associated with non-syndromic cleft lip with or without cleft palate. Biochem Biophys Res Commun. 377(4): 1265-8.
  • Katayama A, et al. (2007) Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: possible involvement in tumor proliferation and prognosis. Int J Oncol. 31(3): 517-24.
彩票大奖得主捐赠 黄大仙论坛精选六肖黄大仙 哪个平台可以买上海时时乐 5分快三大小单双走势图 安徽快3开奖视频 股票配资平台推广 贵州11选5下期推荐 国际期货配资 新疆11选5黄金码 股票开户哪家证券公司好知乎 快乐赛车预测